Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07238322 · ClinicalTrials.gov registry record
[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
A clinical trial of Glioma and Brain Neoplasms, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- Active
- Registry status
- 400
- Enrollment target
- 4
- Study locations
NCT07238322: Active study of Glioma and Brain Neoplasms, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
NCT07238322 is a study of Glioma and Brain Neoplasms that is active but no longer recruiting, run by Telix Pharmaceuticals (Innovations) Pty Limited. The registered enrollment target is 400 participants, above the 205-participant average among 87 other Glioma trials with a reported enrollment target (95% higher). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07238322, a study of Glioma and Brain Neoplasms, is active but no longer recruiting, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- ACTIVE NOT RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is designed to prospectively analyze \[18F\]FET PET image data obtained retrospectively in the routine clinical care of glioma patients. The study will analyse the data from participants with grade (1-4) glioma after primary treatment according to local clinical practice and with suspicion of progression/recurrence on magnetic resonance imaging (MRI).
Primary Outcome
The performance of \[18F\]FET PET in its ability to differentiate between benign treatment-related changes (TRC) and recurrent glioma (Grades 1-4) in comparison to a composite standard of truth (CSOT) will be evaluated and sensitivity and specificity evaluated.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST 18F(FET)PET
Study Locations (4)
Other
- University Hospital Essen - Essen
- Universityhospital Tuebingen - Tübingen
- The University Medical Center Utrecht - Utrecht
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2026-02-23 |
What the registry record for NCT07238322 still lists
NCT07238322 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 205-participant average among 87 other Glioma trials with a reported enrollment target (95% higher).
The record links to 3 conditions, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which 18F(FET)PET is the first listed.
NCT07238322 reports a single indexed study location in Other, California.
Frequently Asked Questions
What is clinical trial NCT07238322 about?
NCT07238322 is a clinical study titled "[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes". This study is designed to prospectively analyze \[18F\]FET PET image data obtained retrospectively in the routine clinical care of glioma patients. The study will analyse the data from participants with grade (1-4) glioma after primary treatment according to local clinical practice and with suspicio...
What is the current status of trial NCT07238322?
This trial is currently active not recruiting. The enrollment target is 400 participants. The study started on 2025-09-22. Estimated completion is 2026-02-23.
What conditions does trial NCT07238322 study?
This clinical trial studies the following conditions: Glioma, Brain Neoplasms, Retrospective Study.
What interventions are being tested in trial NCT07238322?
The interventions under investigation include: 18F(FET)PET (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07238322?
This trial is sponsored by Telix Pharmaceuticals (Innovations) Pty Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07238322 being conducted?
This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07238322's enrollment target sits among peer trials
400 3rd of 87 higher than 85 of 87 other Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
RECRUITING · Phase 2
-
Tumor Treating Fields for the Treatment of Brainstem Gliomas
RECRUITING · NA
-
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RECRUITING · Phase 4
-
Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks
RECRUITING
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI